LAURIE MACCASKILL PARTNERS WITH CANCERCONNECT

(October 19, 2018)

For Immediate Release MacCaskill to bring her inspirational story of survival to the Pancreatic and Cancer Connect Communities KETCHUM – LOS ANGELES:  Laurie MacCaskill, a 12-year survivor of pancreatic cancer and former chair of the Pancreatic Cancer... Continue Reading


Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone

(October 15, 2018)

Penn study shows patients with treatable mutations identified by liquid biopsy also largely respond to therapy October 11, 2018 PHILADELPHIA – In one of the largest clinical studies to ever examine the impact of using a blood test to detect treatable... Continue Reading


More women with early-stage breast cancer may be able to avoid chemotherapy

(October 10, 2018)

Results from a large clinical trial called TAILORx showed that more women with early-stage breast cancer may now be able to avoid chemotherapy after surgery. The women who participated in the study had hormone receptor-positive, HER2-negative, axillary... Continue Reading


Designation for Advanced Cutaneous Squamous Cell Carcinoma

(October 1, 2018)

Breakthrough Designation for Advanced Cutaneous Squamous Cell Carcinoma The U.S. Food and Drug Administration (FDA) has approved cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with... Continue Reading


duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

(September 25, 2018)

The Food and Drug Administration granted regular approval to duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. In... Continue Reading


Clinical Trial Shows Best Outcomes to Date for Older Hodgkin Lymphoma Patients

(September 18, 2018)

Recently published results of a phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine (AVD) chemotherapy,... Continue Reading


First In Class Immunostimulating Anticancer Agent able to Directly Inhibit Tumor Signaling and Kill Tumor Cells, is in Clinical Trial for Glioblastoma and Melanoma Metastatic to the Brain

(September 13, 2018)

Small molecule lead drug candidate blocks a critical target for tumors and crosses the blood brain barrier; begins first brain cancer patient dosing in clinical trial at MD Anderson Cancer Center HOUSTON, TX – September 13, 2018 – In the ongoing... Continue Reading


Targeted Combination Treatment for Melanoma now Available

(September 10, 2018)

The US Food and Drug Administration (FDA) approved the combination of Bratovi (encorafenib) and Mektovi (binimetinib)for use in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. About... Continue Reading


AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström’s Macroglobulinemia, a Rare Type of Blood Cancer

(September 4, 2018)

PRESS RELEASE PR Newswire Aug. 27, 2018, 07:00 AM NORTH CHICAGO, Ill., Aug. 27, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved... Continue Reading


Immune-mediated Nephritis Reported to Occur with Tecentriq®

(August 30, 2018)

Immune-mediated Nephritis Reported to Occur with Tecentriq® Enough patients have developed immune-mediated nephritis which has been biopsy-confirmed in many cases that the manufacturer of Tecentriq now considers this to be an important adverse reaction. ... Continue Reading


About The National Ovarian Cancer Coalition

(August 29, 2018)

Where do you go when you’re first delivered the news: “You have cancer”? For many women diagnosed with ovarian cancer, the answer is the National Ovarian Cancer Coalition (NOCC). With more than 80 chapters nationwide, a Web site (www.ovarian.org)... Continue Reading


Opdivo® (nivolumab) Approved for Treatment of Small Cell Lung Cancer

(August 23, 2018)

The U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the treatment of metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy.1 About Small... Continue Reading


Next Page »